patients with advanced cancers underwent in-house NGS, including tumor mutational burden (TMB) and pharmacogenomics.
First-pass extracted concept
in-house next-generation sequencing
Candidate: concept label1 source documents5 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
in-house NGS
Evidence Snippets
Supporting Sources
Linked Claims
RNA and tumor mutational burden analyses were successful in 89.2% and 86.5% of patients, respectively.
Quoted textsource-backed
RNA and TMB analyses were successful in 89.2% and 86.5% of patients, respectively.
The program identified 54.2% of patients as candidates for on-label or off-label FDA-approved therapies.
Quoted textsource-backed
A total of 54.2% of patients were identified as candidates for use of on- or off-label FDA-approved therapies
In-house NGS was completed within an average of 11 business days and was performed in 251 of 279 patients in the program.
Quoted textsource-backed
In-house NGS, completed within 11 business days on average, was performed in 90% (251) of the 279 patients in the KCGI with advanced cancers.
Nearly all patients who underwent pharmacogenomics testing had at least one gene alteration associated with medication dose adjustment or avoidance.
Quoted textsource-backed
99.6% of patients who underwent pharmacogenomics testing had at least one gene alteration associated with medication dose adjustment/avoidance.
In-house NGS with an adaptable bioinformatics pipeline and an established molecular tumor board improved genomics-guided care processes at a community-based academic cancer center.
Quoted textsource-backed
the utilization of in-house NGS with an adaptable bioinformatics pipeline and the establishment of an MTB enabled the refinement of institutional processes and created an environment that enhanced clinician interest in genomics and improved genomics-guided care for patients with advanced cancers.